← Leaderboards
Clifford Jack
University Of California Berkeley
$41,696,239
Attributed
$65,403,365
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$65,403,365 · 21
By mechanism
R01$22,807,622 · 5
U01$19,740,997 · 1
U24$9,258,005 · 1
R37$6,020,428 · 1
U19$5,955,175 · 2
P50$1,121,433 · 2
Top collaborators
- David S Knopman10 shared
- William J. Jagust7 shared
- Ronald C Petersen6 shared
- Phillip A Low5 shared
- Jonathan Graff-Radford4 shared
- Wolfgang Singer4 shared
- Prashanthi Vemuri4 shared
- Michelle M Mielke2 shared
Most similar at University Of California Berkeley
Same institution · by research overlap
- Michael Lustig$7,877,045
- William J. Jagust$34,577,860
- Chunlei Liu$16,012,758
- Silvia A. Bunge$4,437,002
- Nina F. Dronkers$4,805,996
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMagnetic Resonance ImagingDementiaS DiseaseAgingImagePositron-Emission TomographyGrantCohortBiological MarkersBrainBaseAmyloidNerve DegenerationCognitivePopulation BasedTau ProteinsSymptomsLabelMild Cognitive ImpairmentInsightElderlyImaging ModalityFuture
Grant awards (85)
MRI Core$2,307,265
U19 · FY2025 · AG · contact PI
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$1,580,400
U24 · FY2025 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$770,061
R37 · FY2025 · AG · contact PI
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$1,590,871
U24 · FY2024 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$785,776
R37 · FY2024 · AG · contact PI
Alzheimers Disease Patient Registry$3,907,919
U01 · FY2023 · AG
MRI Core$2,098,261
U19 · FY2023 · AG · contact PI
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$1,602,013
U24 · FY2023 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$801,126
R37 · FY2023 · AG · contact PI
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$582,629
U24 · FY2023 · AG
Alzheimers Disease Patient Registry (Administrative Supplement)$301,515
U01 · FY2023 · AG
Alzheimers Disease Patient Registry$3,907,919
U01 · FY2022 · AG
MRI Core$1,549,649
U19 · FY2022 · AG · contact PI
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$732,693
R37 · FY2022 · AG · contact PI
Alzheimers Disease Patient Registry$3,874,548
U01 · FY2021 · AG
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$1,603,332
U24 · FY2021 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$732,693
R37 · FY2021 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2021 · AG · contact PI
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$641,593
U24 · FY2021 · AG
Alzheimers Disease Patient Registry$3,874,548
U01 · FY2020 · AG
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging$1,657,167
U24 · FY2020 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$732,693
R37 · FY2020 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2020 · AG · contact PI
Alzheimers Disease Patient Registry$3,874,548
U01 · FY2019 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$732,693
R37 · FY2019 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2019 · AG · contact PI
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$575,041
R01 · FY2019 · NS
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers$732,693
R37 · FY2018 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2018 · AG · contact PI
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$559,929
R01 · FY2018 · NS
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2017 · AG · contact PI
Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers$564,206
R01 · FY2017 · AG · contact PI
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$561,241
R01 · FY2017 · NS
Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers$571,422
R01 · FY2016 · AG · contact PI
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$539,479
R01 · FY2016 · NS
Validating the New Criteria for Preclinical Alzheimer's disease$522,972
R01 · FY2016 · AG · contact PI
Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers$554,280
R01 · FY2015 · AG · contact PI
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$542,627
R01 · FY2015 · NS
Validating the New Criteria for Preclinical Alzheimer's disease$507,281
R01 · FY2015 · AG · contact PI
Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers$571,560
R01 · FY2014 · AG · contact PI
Validating the New Criteria for Preclinical Alzheimer's disease$548,125
R01 · FY2014 · AG · contact PI
Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers$559,671
R01 · FY2013 · AG · contact PI
Validating the New Criteria for Preclinical Alzheimer's disease$521,028
R01 · FY2013 · AG · contact PI
Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging$934,653
R01 · FY2012 · AG · contact PI
Validating the New Criteria for Preclinical Alzheimer's disease$551,354
R01 · FY2012 · AG · contact PI
Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging$968,365
R01 · FY2011 · AG · contact PI
DIFFUSION TENSOR IMAGING ANALYSIS$20,271
P41 · FY2011 · RR · contact PI
Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging$1,034,999
R01 · FY2010 · AG · contact PI
DIFFUSION TENSOR IMAGING ANALYSIS$3,039
P41 · FY2010 · RR · contact PI
Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging$1,043,699
R01 · FY2009 · AG · contact PI
Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging$237,227
R01 · FY2009 · AG · contact PI
DIFFUSION TENSOR IMAGING ANALYSIS$3,406
P41 · FY2009 · RR · contact PI
Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging$868,308
R01 · FY2008 · AG · contact PI
Tensor Atrophy Measures: Structural MRI in Normal Aging, Alzheimer's & FTD$195,992
P50 · FY2008 · AG · contact PI
IN VIVO VISUALIZATION OF ALZHEIMERS AMYLOID PLAQUES BY MRI TRANSGENIC MICE WITH$89,175
P41 · FY2008 · RR · contact PI
MRI OF ALZHEIMER'S PATHOLOGY IN BRAINS OF TRANSGENIC MICE$53,505
P41 · FY2008 · RR · contact PI
DIFFUSION TENSOR IMAGING ANALYSIS$2,576
P41 · FY2008 · RR · contact PI
MRI Biomarkers of Risk and Progression in Alzheimer's$603,795
R01 · FY2007 · AG · contact PI
Tensor Atrophy Measures: Structural MRI in Normal Aging, Alzheimer's & FTD$202,275
P50 · FY2007 · AG · contact PI
IN VIVO VISUALIZATION OF ALZHEIMERS AMYLOID PLAQUES BY MRI TRANSGENIC MICE WITH$106,251
P41 · FY2007 · RR · contact PI
MRI Biomarkers of Risk and Progression in Alzheimer's$703,181
R01 · FY2006 · AG · contact PI
TENSOR ATROPHY MEASURES FROM MRI IN NORMAL AGING /AD/FTD$176,240
P50 · FY2006 · AG · contact PI
IN VIVO VISUALIZATION OF ALZHEIMERS AMYLOID PLAQUES BY MRI TRANSGENIC MICE WITH$109,424
P41 · FY2006 · RR · contact PI
MRI Biomarkers of Risk and Progression in Alzheimer's$717,596
R01 · FY2005 · AG
TENSOR ATROPHY MEASURES FROM MRI IN NORMAL AGING /AD/FTD$172,463
P50 · FY2005 · AG
IN VIVO VISUALIZATION OF ALZHEIMERS AMYLOID PLAQUES BY MRI TRANSGENIC MICE WITH$112,058
P41 · FY2005 · RR
MRI Biomarkers of Risk and Progression in Alzheimer's$715,844
R01 · FY2004 · AG
Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI$339,625
R01 · FY2004 · AG
TENSOR ATROPHY MEASURES FROM MRI IN NORMAL AGING /AD/FTD$168,795
P50 · FY2004 · AG
MRI Biomarkers of Risk and Progression in Alzheimer's$714,182
R01 · FY2003 · AG
Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI$339,625
R01 · FY2003 · AG
Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI$339,625
R01 · FY2002 · AG
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE$241,098
R01 · FY2002 · AG
CORE--NEUROIMAGING$0
P50 · FY2002 · AG
CORE--NEUROIMAGING$0
P50 · FY2002 · AG
CORE--NEUROIMAGING$0
P50 · FY2002 · AG
Alzheimer's Diagnosis by Real-Time Motion Corrected FMRI$339,625
R01 · FY2001 · AG
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE$260,526
R01 · FY2001 · AG
CORE--NEUROIMAGING$0
P50 · FY2001 · AG
CORE--NEUROIMAGING$0
P50 · FY2001 · AG
CORE--NEUROIMAGING$0
P50 · FY2001 · AG
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCE$274,098
R01 · FY2000 · AG
SURGICAL PLANNING WITH REAL TIME MOTION CORRECTED FMRI$219,375
R01 · FY2000 · CA
CORE--NEUROIMAGING$205,668
P50 · FY2000 · AG
CORE--NEUROIMAGING$0
P50 · FY2000 · AG